Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

This study found that a transdermal delivery system using 3% azone and P407 gel may enhance the skin permeation of doxazosin and finasteride for treating benign prostatic hyperplasia.

Doxazosin and finasteride negatively affect sexual function in men with BPH.

This study found that finasteride was nongenotoxic in Drosophila, while doxazosin mesylate and saw palmetto induced homologous recombination, indicating potential genotoxic actions under the test conditions.

This review discusses trials on therapies for benign prostatic hyperplasia and reports that combination treatment is more effective than monotherapy for symptom relief and slowing disease progression in men with moderate to severe symptoms and enlarged prostate glands.

This study reported that doxazosin may result in gynecomastia after administration but evidence and expert reviews on this are still lacking domestically.

This study observed that long-term treatment with 5ARIs in men with LUTS/BPH was linked to worsening sexual function, whereas doxazosin alone had minimal negative impact.

This study found that in rats, combined treatment with finasteride and doxazosin altered epithelial cell behavior and matrix metalloproteinases activity, suggesting effects possibly mediated by TGF-β1 and androgen pathways.

This study found that the combination of finasteride and doxazosina was more effective in reducing the long-term progression of benign prostatic hyperplasia compared to monotherapy.

This update provides information on new drug approvals but does not offer new clinical research findings.

This study presents a validated HPTLC method for simultaneously determining five BPH drugs, showing high sensitivity and selectivity for potential use in quality-control analysis.

This study found that combination therapy with doxazosin and finasteride was more effective in preventing the clinical progression of benign prostatic hyperplasia than either drug alone.

This study found that patients with bladder outlet obstruction and moderately enlarged prostates are likely to successfully discontinue the a-blocker doxazosin after 9 months of combination therapy with finasteride.

This study validated a new RP-HPLC method for accurately determining doxazosin mesylate and finasteride in bulk powders and capsule formulations.

Finasteride interacts with terazosin, but not doxazosin; caution needed.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

Combining medications is more effective for treating benign prostatic syndrome symptoms.

This review discusses various adverse skin reactions linked to cardiovascular medications and reports no new clinical results, highlighting the need for vigilance when prescribing these drugs.

This study found that combining 4 mg doxazosin with 0.2 mg tamsulosin improved urinary symptoms with fewer vasodilatory side effects compared to a higher dose of doxazosin in hypertensive males with LUTS.

This case report documents a 59-year-old man in Taiwan who developed breast cancer while undergoing finasteride therapy for benign prostate hyperplasia, marking a rare side effect.

This editorial comment reports no new clinical findings, instead discussing a study on the effectiveness of combination therapy with doxazosin and finasteride in patients with benign prostatic hyperplasia.

In this study, Nephrolepis biserrata extract significantly improved fertility indices in male Wistar rats with testosterone propionate-induced benign prostatic hyperplasia, showing increased sperm count and reduced prostate weight, suggesting potential pro-fertility benefits for BPH-related infertility.

This study demonstrated that the pharmacokinetic profiles of finasteride and doxazosin remain bioequivalent when administered in combination compared to when each drug is taken alone.

This study found that the combination therapy of Flosin and Prostamol Uno over nine years was well tolerated and equally effective in managing benign prostatic hyperplasia symptoms as the combination of doxazosin and finasteride, with fewer adverse events reported.

This study suggested that minoxidil's neuroprotective effect in mice was independent of its blood pressure-lowering action, unlike the effects observed with losartan and doxazosin.